Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program
Persistence and adherence to tildrakizumab were high through 52 weeks of treatment among patients with moderate-to-severe plaque psoriasis enrolled in the Canadian PSP.
Authors
- Deepa Gopalan (ORCID: https://orcid.org/0000-0001-8079-205X)
- Vimal H. Prajapati (ORCID: https://orcid.org/0000-0002-8315-2522)
- Maxwell Benjamin Sauder (ORCID: https://orcid.org/0000-0002-5605-3844)
- Pak Chan
- Nicole Bellefontaine
- Rommel Mangaser
Institutions
- University of Toronto (CA)
- Brampton Civic Hospital (CA)
- Bayer (Canada) (CA)
- Probity Medical Research (CA)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1007/s13555-025-01434-x
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Sun Pharma